Compare LOMA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOMA | CGEM |
|---|---|---|
| Founded | 1926 | 2016 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | LOMA | CGEM |
|---|---|---|
| Price | $11.61 | $16.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $15.00 | ★ $30.13 |
| AVG Volume (30 Days) | 344.0K | ★ 553.4K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.53 | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.04 | $5.68 |
| 52 Week High | $13.20 | $19.43 |
| Indicator | LOMA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 47.07 |
| Support Level | $11.37 | $16.00 |
| Resistance Level | $12.18 | $19.10 |
| Average True Range (ATR) | 0.45 | 0.91 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 42.97 | 35.42 |
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The Group is engaged in the production and distribution of cement, masonry cement, concrete, limestone, and aggregates, operates a railway concession to provide transportation services, and is also engaged in the industrial waste recycling business. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.